Pages that link to "Q417296"
Jump to navigation
Jump to search
The following pages link to febuxostat (Q417296):
Displayed 50 items.
- hyperuricemia (Q49970) (← links)
- gout (Q133087) (← links)
- (Q3740639) (redirect page) (← links)
- Adenuric (Q29004386) (← links)
- Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease (Q34317722) (← links)
- Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout (Q38365938) (← links)
- Uloric (Q47522249) (← links)
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment (Q61894552) (← links)
- Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (Q61907330) (← links)
- Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) (Q61936051) (← links)
- Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones (Q61938043) (← links)
- Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure (Q61955424) (← links)
- Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat (Q61956138) (← links)
- Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI) (Q62031639) (← links)
- Febuxostat Versus Allopurinol Control Trial in Subjects With Gout (Q62106265) (← links)
- Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction (Q62815070) (← links)
- Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers (Q63316008) (← links)
- Effect of Febuxostat on Blood Pressure (Q63319101) (← links)
- Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients (Q63322868) (← links)
- Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease (Q63334830) (← links)
- Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) (Q63338447) (← links)
- Effect of Hyperuricaemia on Chronic Renal Disease (Q63401717) (← links)
- Uric Acid Effects on Endothelium and Oxydative Stress (Q63403715) (← links)
- A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (Q63805552) (← links)
- A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA (Q63811368) (← links)
- Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions (Q64139892) (← links)
- Safety and Efficacy of Oral Febuxostat in Subjects With Gout (Q64221676) (← links)
- The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study (Q64640394) (← links)
- Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. (Q64997372) (← links)
- Gout: Allopurinol vs. Febuxostat (Q65316390) (← links)
- Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout (Q65342669) (← links)
- The Effect of Uric Acid Lowering in Type 1 Diabetes (Q65348789) (← links)
- Compare the Renal Protective Effects of Febuxostat and Benzbromarone (Q65349803) (← links)
- The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients (Q65349852) (← links)
- Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients (Q66079622) (← links)
- Zurig (Febuxostat) 40mg Efficacy and Safety Trial (Q67126594) (← links)
- Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy (Q74287330) (← links)
- The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients:A Prospective Cohort Study (Q83793931) (← links)
- A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout (Q90156318) (← links)
- Inhibition of xanthine oxidoreductase protects against contrast-induced renal tubular injury by activating adenosine monophosphate-activated protein kinase (Q90331149) (← links)
- Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients (Q91571724) (← links)
- Freeze-Dried Self-Nanoemulsifying Self-Nanosuspension (SNESNS): a New Approach for the Preparation of a Highly Drug-Loaded Dosage Form (Q92096802) (← links)
- Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis (Q92120306) (← links)
- The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males (Q92207864) (← links)
- Role of Uralyt-U in Patients With Hyperuricemia (Q92273624) (← links)
- The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis (Q92396624) (← links)
- Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data (Q92668144) (← links)
- Effects of febuxostat on atrial remodeling in a rabbit model of atrial fibrillation induced by rapid atrial pacing (Q92858040) (← links)
- The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice (Q92867424) (← links)
- Febuxostat attenuates ulcerative colitis by the inhibition of NF-κB, proinflammatory cytokines, and oxidative stress in mice (Q93198555) (← links)